An injection takes five minutes in a doctor's office
In the ongoing effort to make COVID-19 treatments more accessible, Vir Biotechnology and GlaxoSmithKline asked the FDA in January 2022 to permit their monoclonal antibody sotrovimab to be delivered by intramuscular injection — not just intravenous infusion. The request reflects a quiet but meaningful shift in pandemic medicine: from the urgency of developing therapies to the harder, slower work of making them reachable for the people who need them most. For high-risk patients in rural communities or overwhelmed healthcare systems, the difference between a hospital infusion and a clinic injection is not merely logistical — it can determine whether treatment happens at all.
- Sotrovimab has been available to high-risk COVID patients, but only through IV infusion — a process that demands clinical infrastructure many patients cannot easily access.
- The gap between having an effective treatment and being able to deliver it is creating real consequences, particularly during surges when hospitals are stretched thin.
- Vir and GSK are pushing to add intramuscular injection as an approved route, a simpler method that could be administered in a doctor's office or clinic without a full infusion setup.
- The FDA must verify that the drug performs safely and effectively via this new route before updating its authorization — a rigorous review that is far from automatic.
- Markets responded with modest optimism, reflecting cautious investor confidence rather than certainty about the outcome.
- If approved, the change would mark a broader evolution in pandemic response — from getting treatments approved to making them genuinely usable.
In January 2022, Vir Biotechnology and GlaxoSmithKline formally asked the FDA to expand how sotrovimab — their monoclonal antibody for high-risk COVID patients — could be administered. Originally authorized only for intravenous infusion, the drug would, if the request is approved, also be available via intramuscular injection.
The distinction matters more than it might first appear. IV infusion requires a medical facility, a scheduled appointment, and clinical infrastructure that isn't always available — especially in rural areas or during hospital surges. An intramuscular injection, by contrast, can be given in a standard clinic or doctor's office, removing barriers that have quietly limited who can actually receive the treatment.
For elderly, immunocompromised, or otherwise vulnerable patients, that accessibility gap can shape outcomes in concrete ways. The difference between a treatment that requires a hospital visit and one available at a local clinic may determine whether a patient seeks care early enough to benefit.
The FDA will need to review evidence that sotrovimab is absorbed safely and effectively through this new route — a serious evaluation, since the method of delivery affects how a drug behaves in the body. Neither company's stock moved dramatically on the news, though both edged upward, reflecting measured investor optimism.
The request itself signals something larger about where pandemic medicine now stands. With effective treatments already in hand, the challenge has shifted to distribution and access. Sotrovimab via intramuscular injection is not a new drug — it is an attempt to make an existing one work better for the people who need it most.
On Thursday, Vir Biotechnology and GlaxoSmithKline made a formal request to the Food and Drug Administration to expand how their COVID-19 treatment can be delivered to patients. The two companies asked the agency to update its authorization for sotrovimab—a monoclonal antibody designed to prevent severe illness in high-risk teenagers and adults—to permit intramuscular injection in addition to the intravenous infusion method that was originally approved.
Sotrovimab works by supplying antibodies that help the immune system fight the virus before it can cause serious disease. The drug has been available since its initial authorization, but only through the traditional route of an IV drip, which requires patients to visit a medical facility and sit for an infusion appointment. That logistical requirement has real consequences: it limits where and when people can access the treatment, and it demands clinical infrastructure that isn't always readily available, especially in rural areas or during surges when hospitals are overwhelmed.
The request to add intramuscular administration—a simple injection into muscle tissue, similar to a vaccine or many other common treatments—represents a practical shift in how the therapy could reach patients. An injection can be given in an office, clinic, or potentially even at home with proper training, removing barriers that an infusion-only approach creates. For patients who are immunocompromised, elderly, or otherwise at genuine risk of hospitalization from COVID-19, faster and easier access to a preventive treatment could meaningfully change outcomes.
Vir's stock moved up 1.0% on the day the announcement was made, while GSK shares ticked up 0.1%. The broader market context matters: Vir stock had fallen 3.8% year-to-date at that point, and GSK was up 2.7% over the same period. The S&P 500 itself had declined 0.8%, so the modest gains for both companies reflected some investor optimism about the regulatory request, though neither stock surged dramatically on the news.
The FDA would need to review data from the companies showing that intramuscular injection delivers sotrovimab safely and effectively—that the drug works just as well when given this way, and that patients tolerate it without unexpected side effects. This is not a trivial change; how a drug is administered affects how it's absorbed, how quickly it reaches therapeutic levels in the bloodstream, and what the patient experience looks like. The agency takes such modifications seriously and requires solid evidence before updating an authorization.
If approved, the change would reshape the practical landscape of COVID-19 treatment during a period when the virus remained a significant public health concern. It would mean that people at high risk could potentially access sotrovimab without the friction of scheduling an infusion appointment, traveling to a facility, and spending time in a medical setting. For some patients, that difference between "I can get this at my doctor's office" and "I need to go to the hospital" could be the difference between actually receiving the treatment and putting it off until symptoms worsen.
The request also signals how pharmaceutical companies and regulators think about treatment access as the pandemic evolves. Early in the COVID-19 crisis, getting any effective therapy approved was the priority. Now, with multiple treatments available, the focus shifts to making those treatments practical and accessible. An intramuscular option for sotrovimab fits that evolution—it's not a new drug, but a smarter way to deliver one that already exists.
Citas Notables
The companies asked the FDA to update its authorization for sotrovimab to permit intramuscular injection in addition to the intravenous infusion method— Vir Biotechnology and GlaxoSmithKline
La Conversación del Hearth Otra perspectiva de la historia
Why does the route of administration matter so much? Isn't the drug the same either way?
The drug is the same, but how it gets into your body changes everything about access. An IV infusion requires you to sit in a medical facility for an appointment. An injection takes five minutes in a doctor's office. For someone who's immunocompromised and trying to prevent severe illness, that difference is real.
So this is really about convenience, not efficacy?
It's about both. The companies have to prove to the FDA that the drug works just as well when injected into muscle instead of dripped into a vein. But yes, if it works equally well, then convenience becomes the point—and convenience is access.
Who benefits most from this change?
People at high risk—elderly patients, immunocompromised people, those with certain chronic conditions. They're the ones who need sotrovimab most, and they're often the ones least able to navigate a hospital infusion appointment. An injection at their regular doctor's office removes a real barrier.
What happens now? Does the FDA just say yes?
The FDA will want to see data. The companies need to show that intramuscular injection is safe and that the drug reaches therapeutic levels in the bloodstream the same way it does with an IV. It's not automatic, but it's a reasonable request based on how the drug works.
Why are the stock prices barely moving if this is good news?
Because it's a modification to an existing drug, not a breakthrough. Investors care about new revenue streams and market expansion. This helps with access and potentially sales, but it's not transformative. It's smart, practical work—just not the kind that makes markets jump.